Advertisement

Topics

Latest "Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel" News Stories

01:57 EST 19th November 2018 | BioPortfolio

Here are the most relevant search results for "Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel" found in our extensive news archives from over 250 global news sources.

More Information about Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel for you to read. Along with our medical data and news we also list Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel Clinical Trials, which are updated daily. BioPortfolio also has a large database of Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel Companies for you to search.

Showing "Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel" News Articles 1–25 of 914

Saturday 17th November 2018

News digest – NHS staff shortages, cervical screening error, HPV jab catch-up and ‘fat-clogged’ cells

Science blog NHS staff shortages could reach 350,000 by 2030 The NHS faces a growing staff crisis that could leave hospitals short of 350,000 staff by 2030, reports The Guardian. The figures come from three leading health sector think tanks, who warn that not addressing the staffing gap could lead to spiralling waiting times and worsening patient care. We’ve estimated that NHS cancer staff nu...


Friday 16th November 2018

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

Novartis International AG / FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthro...

Novel Drug Combination Shows Early Activity in Microsatellite Stable CRC

Pixatimod (PG545) in combination with the PD-1 inhibitor nivolumab (Opdivo) may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.


FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas

BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 16, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S....

New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System

Three-Year Data from the ANCHOR Registry Reiterate Applicability in Patients with Hostile Aortic Neck Anatomies DUBLIN and NEW YORK - November 16, 2018 - Medtronic plc (NYSE:MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those ...

Immunicum Collaborates with Merck KGaA and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

Immunicum AB (publ; IMMU.ST) announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial. Immunicum will initiate a study &#...

Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer

Novartis International AG / Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Kisqali is the CDK4/6 inhibitor with the ...

Novartis Receives Positive CHMP Opinion To Expand Kisqali Combination Therapy

BASEL (dpa-AFX) - Novartis (NVS) announced the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion recommending an expande...

Standard chemo still most effective for throat cancers caused by HPV

News report Standard chemotherapy remains the most effective way to treat a particular form of throat cancer, according to new research. Scientists from the University of Birmingham compared the effectiveness of 2 drugs in patients diagnosed with throat cancer caused by an infection with the human papillomavirus (HPV), called HPV-positive throat cancer. They also compared the severity of side e...

Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

Press Release 16 November 2018 Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study Immunicum AB (publ; IMMU.ST) announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead ...

Thursday 15th November 2018

[Articles] Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

For patients with HPV-positive oropharyngeal carcinoma, radiotherapy plus cetuximab showed inferior overall survival and progression-free survival compared with radiotherapy plus cisplatin. Radiotherapy plus cisplatin is the standard of care for eligible patients with HPV-positive oropharyngeal carcinoma.

[Articles] Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Compared with the standard cisplatin regimen, cetuximab showed no benefit in terms of reduced toxicity, but instead showed significant detriment in terms of tumour control. Cisplatin and radiotherapy should be used as the standard of care for HPV-positive low-risk patients who are able to tolerate cisplatin.

What Immunotherapy Combination Is Best in Metastatic Bladder Cancer?

Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.

Celgene Corp CELG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryCelgene Corp Celgene is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immuneinflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza azacitidine for the treatment of myelodysplastic syndromes MDS; Revlimid lenalidomide, Pomalyst pomali...

Drug Combination Makes Cancer Disappear in Mice with Neuroblastoma

NewsResearchers investigating new treatments for neuroblastoma have found that a combination of two drugs made tumors disappear in mice, making it more effective than any other drugs tested in these animals.

Copyright Clearance Center Announces Enhancements to Award-Winning Content Workflow Solution, RightFind®

Delivers Powerful Combination of Content, Rights and Information Expertise, Offering Customers Access to the World’s Largest Collection of Scientific, Technical and Medical Content Copyright Clearance Center, Inc. (CCC), a leader in advancing copyright, accelerating knowledge, and powering innovation, announces enhancements to its award-w...

Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-Hospitalized Patients with Influenza A

Data Demonstrating Reductions in Time to Resolution of Viral Load in Patients and In Vitro Antiviral Activity of VIS410 in Combination with Small Molecule Antivirals Presented at the 6th ISIRV Advances in Respiratory Virus Therapeutics Conference Topline Data from Phase 2b study in Hospitalized Influenza A Patients Requiring Oxygen Support Expecte...

INNATE PHARMA : Third quarter 2018 report

Innate Pharma Third quarter 2018 Report Acceleration of becoming a fully integrated oncology-focused biotech company through a recent landmark deal with AstraZeneca Expansion of oncology development collaboration with AstraZeneca validates Innate's leadership in immuno-oncology discovery Strengthens financial runway by $242 million in total near-term cash proceeds

Wednesday 14th November 2018

Jason Vedadi Acquires Super Voting and Multiple Voting Shares of Harvest Health & Recreation Inc.

On November 14, 2018, Harvest Health & Recreation Inc. (formerly, RockBridge Resources Inc., the “Issuer”), located at 627 S 48th St, Ste 100, Tempe, AZ 85281, and Harvest Enterprises Inc. (“VCP”) completed its previously announced business combination (the “Business Combination”), to create a U.S. based cannabis cultivator, processor and d...

Luye Pharma Group Co Ltd 2186 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250

SummaryLuye Pharma Group Co Ltd Luye Pharma is a pharmaceutical company that develops, produces and markets pharmaceutical products in the therapeutic areas of oncology, cardiovascular, metabolism and central nervous system. The company's products include sodium aescinate for injection, xuezhikang capsule, amifostine for injection, lentinan for injection, arsenious acid and sodium chloride injecti...

Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption

FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Abraxane for PD-L1-Positive Metastatic TNBC

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) ...

FDA Grants Priority Review to Combination Treatment for Initial TNBC

The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 pro...

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Phase 3 KEYNOTE-181 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy in th...

Tuesday 13th November 2018

Combination of two immunotherapies shows activity in non-small cell lung cancer patients

(ECCO-the European CanCer Organisation) A combination of two drugs, which prompt the body's immune system to identify and kill cancer cells, is a safe treatment for patients with advanced non-small cell lung cancer and has shown some signs of efficacy. The research is presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks